XELJANZ (U.S. Pharmaceuticals)


Welcome to the PulseAid listing for the XELJANZ drug offered from U.S. Pharmaceuticals. This Janus Kinase Inhibitor [EPC],Janus Kinase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: U.S. Pharmaceuticals
NON-PROPRIETARY NAME: tofacitinib
SUBSTANCE NAME: TOFACITINIB CITRATE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Janus Kinase Inhibitor [EPC],Janus Kinase Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET, FILM COATED
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2012-11-08
END MARKETING DATE: 0000-00-00


XELJANZ HUMAN PRESCRIPTION DRUG Details:

Item DescriptionXELJANZ from U.S. Pharmaceuticals
LABELER NAME: U.S. Pharmaceuticals
DEA SCHEDULE:
ACTIVE STRENGTH: 5(mg/1)
START MARKETING DATE: 2012-11-08
END MARKETING DATE: 0000-00-00
PRODUCT ID: 63539-012_2dafc9ff-d8b7-4ddd-9496-ecffa83dbf92
PRODUCT NDC: 63539-012
APPLICATION NUMBER: NDA203214

Other TOFACITINIB CITRATE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Pfizer Laboratories Div Pfizer IncXELJANZ
U.S. PharmaceuticalsXELJANZ